Navigation Links
Biomira Selects PX-866 as Clinical Development Candidate and,Presents Promising Preclinical Data at AACR

-IND filing expected by end of 2007-

EDMONTON, April 16, 2007 /PRNewswire-FirstCall/ - Biomira Inc. today announced that it has selected PX-866 as its next clinical development candidate. PX-866 is an inhibitor of the phosphatidylinositol-3-kinase (PI3 kinase)/ PTEN/AKT pathway, an important survival signaling pathway that is activated in many types of human cancer, including glioblastoma. Preclinical data presented this past weekend at the American Association of Cancer Research (AACR) annual meeting demonstrate that PX-866 has activity in an intracranial model of glioma.

"The preclinical data for PX-866, including those presented at AACR, are very promising and warrant advancing this small molecule compound to clinical development," said Robert L. Kirkman, M.D., President and Chief Executive Officer of Biomira. "The data presented this weekend are particularly compelling, as they provide evidence of PX-866 activity in an intracranial model of glioma, a disease that accounts for 77 percent of all malignant brain cancers and is refractory to conventional therapies. We are in the process of completing preclinical studies designed to support the expected filing of an investigational new drug (IND) application for PX-866 later this year. Expanding and advancing our clinical pipeline is a key priority for Biomira, and we are on track to have four programs in clinical development by the end of 2007."

Preclinical data presented at AACR by Dr. Dimpy Koul of The University of Texas M. D. Anderson Cancer Center (MDACC) (Abstract #278) showed that PX-866 treatment resulted in growth inhibition in three different glioma cell lines. The magnitude of the inhibition depended on the status of PTEN in the cell lines, with PTEN-negative cells showing greater sensitivity to PX-866. Treatment with PX-866 inhibited activation of AKT and other downstream targets of PI3K. A dose-dependent increase in autophagy, a type
'"/>




Page: 1 2 3

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:5/28/2015)... Lilly and Company (NYSE: LLY ) announced today the ... up to $1.6 billion aggregate principal amount of certain of ... tendered, and did not validly withdraw, their notes on or ... time, on May 27, 2015 (the early tender date), and ... receive the total consideration. The total consideration for each series ...
(Date:5/28/2015)... VANCOUVER and HOUSTON , May ... "Company") (TSX-V: EPI) today reported financial results for the second ... Amounts, unless specified otherwise, are expressed in Canadian dollars and ... Summary Results ESSA recorded a net ... six months ended March 31, 2015 (Q2-2015), compared to a ...
(Date:5/28/2015)... , May 28, 2015 ... announced the addition of Jain PharmaBiotech,s new ...  to their offering.       ... or gene silencing involves the use of ... cell, this material is processed into short ...
Breaking Medicine Technology:Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 3Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 4Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 5Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3
... 2011 Dynatronics Corporation (NASDAQ: DYNT ) today announced ... 2011. Sales for the quarter ended June 30, 2011 ... ended June 30, 2010. Sales for the year ended June 30, ... the prior year. Net income for the quarter ...
... Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... subsidiary, Valeant International (Barbados) SRL, has received notice that ... oral bile acid sequestrant for hypercholesterolemia, has been approved ... "Cardiovascular Disease is the cause of one in ...
Cached Medicine Technology:Dynatronics Announces Fourth Quarter and Year-end Results 2Dynatronics Announces Fourth Quarter and Year-end Results 3Dynatronics Announces Fourth Quarter and Year-end Results 4Valeant Pharmaceuticals Announces Approval Of Colesevelam Hydrochloride In Canada 2Valeant Pharmaceuticals Announces Approval Of Colesevelam Hydrochloride In Canada 3Valeant Pharmaceuticals Announces Approval Of Colesevelam Hydrochloride In Canada 4
(Date:5/29/2015)... 2015 Abington Hospital – Jefferson ... first hospitals in the nation to join the ... practices and work toward achieving the Baby-Friendly USA© ... focusing on maternity care practices leading to Baby-Friendly ... and Prevention, EMPower is aimed at increasing breastfeeding ...
(Date:5/29/2015)... can mark one more item off her bucket list: skydiving. ... community is the oldest woman to have flown at an indoor ... she exclaimed. “I’ve always wanted to jump from an airplane ... would be ok.” , “We put on nylon coveralls, helmets, and ... “I don’t remember it being noisy, but the wind was blowing ...
(Date:5/29/2015)... Carolina (PRWEB) May 29, 2015 Red ... that the newest Red Hot & Blue restaurant at 525 ... on Thursday, May 7, 2015. “The Red Hot & Blue ... for 18 years, but we have moved to a new ... now in the middle of all the activities on the ...
(Date:5/29/2015)... York, NY (PRWEB) May 29, 2015 ... unit have reached a confidential Risperdal lawsuit ( ... allegedly developed gynecomastia due to his use of ... case had been selected for the third bellwether ... a mass tort litigation underway in Pennsylvania’s Philadelphia ...
(Date:5/29/2015)... 29, 2015 World Patent Marketing, a ... that it has signed a 10 year licensing agreement ... aims to let people learn about any topic and ... , "This is an exciting day for World Patent ... J. Cooper, CEO and Creative Director of World Patent ...
Breaking Medicine News(10 mins):Health News:Abington Hospital Selected to Join Baby-Friendly Hospital Initiative 2Health News:Indoor Skydiving Brings Thrills to Seniors 2Health News:Red Hot & Blue Restaurant Opens in Cary, North Carolina 2Health News:Red Hot & Blue Restaurant Opens in Cary, North Carolina 3Health News:Red Hot & Blue Restaurant Opens in Cary, North Carolina 4Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 2Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 3Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 2Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 3Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 4Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 5
... ... International, a global multi-level marketing company, promotes launch of business operations in Ukraine. ... Kyiv, Ukraine (PRWEB) June ... On May 30th, Sisel Founder and Chairman Tom Mower Sr. was in the Ukrainian capital ...
... After months of ... online buying a simple, easy one-stop shopping experience. , ... (PRWEB) June 5, 2010 -- With online shopping growing in popularity, ... arrangements and payment procedures that it is easy to get confused, which can lead to ...
... new research that will be presented on Saturday, June 5, ... Dental Sleep Medicine, the majority of U.S. dental schools have ... which affect more than 70 million adults in the U.S. ... Angeles (UCLA) School of Dentistry surveyed each of the 58 ...
... be presented on Saturday, June 5, at the 19th Annual ... may help dentists predict oral appliance therapy success in sleep ... the nasal cavity. The tip of the scope is placed ... has been shown to be a safe and effective treatment ...
... to new research that will receive the Graduate ... the 19th Annual Meeting of the American Academy ... screen for sleep-disordered breathing (SDB) in a pediatric ... resistance syndrome, and snoring. The researchers evaluated ...
... ... Refrigerated Vacuum Pak or Modified Atmosphere Packaged Raw Fish and Fishery Product”, or Import ... or vacuum packed, raw seafood into the US. , ... (Vocus) June 7, 2010 -- “Detention Without Physical ...
Cached Medicine News:Health News:SISEL International Holds Successful Launch Events In Ukraine 2Health News:SISEL International Holds Successful Launch Events In Ukraine 3Health News:BestMassage.com Launches Its Brand New Customer-Focused Website 2Health News:US dental schools leave graduates unprepared to screen for sleep disorders 2Health News:Nasendoscopy proves useful in predicting treatment success in sleep apnea patients 2Health News:Questionnaires help dentists screen for sleep-disordered breathing in children 2Health News:FDA Issues Global Raw Packaged Seafood Import Alert: FDAImports.com Reports Numerous International Firms Impacted 2Health News:FDA Issues Global Raw Packaged Seafood Import Alert: FDAImports.com Reports Numerous International Firms Impacted 3
... ADVANCE Rapid HIV-1/2 Antibody ... qualitative immunoassay to detect ... Virus Type 1 (HIV-1) ... in oral fluid, fingerstick ...
The Becton™ Colles Fracture Plate has proven clinical outcomes and has excellent patient acceptance compared to external fixation. It provides a cost effective treatment option through a simple...
Standard Trephine...
Coronet Vacuum Trephine - All metal, ergonomic design and ultra sharp blade with cross hairs....
Medicine Products: